Loading
Life sciences · Journal article
Celal Bayar Üniversitesi Fen Bilimleri Dergisi · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Betaine, a naturally occurring zwitterion, was evaluated for its anticancer potential against murine 4T1 breast cancer cells and non-cancerous L929 fibroblast cells. Cells were treated with various concentrations for 48 hours, and viability was assessed using the MTT assay. Betaine showed weak, dose-dependent cytotoxicity with an IC50 value of 859.10 µg/mL. In silico ADME analysis showed high solubility, low lipophilicity (LogP: –2.18), and poor blood-brain barrier permeability. ProTox-II predicted low hepatotoxicity, nephrotoxicity, and immunotoxicity, but possible neurotoxic and cardiotoxic effects. Betaine was non-carcinogenic and showed no significant interaction with major metabolic enzymes. These findings suggest that while betaine has limited direct cytotoxicity, its favorable safety and pharmacokinetic profile support its potential as an adjuvant in cancer therapy.